First GLP‑1 pill OK'd

Glucagon-like peptide-1 drugs copy a gut hormone that slows stomach emptying and cuts appetite, and the Food and Drug Administration has now cleared the first pill version for chronic weight management: once-daily Wegovy tablets, which contain semaglutide. (ajmc.com) The agency approved oral semaglutide on December 22, 2025, for adults with obesity, or with overweight plus at least one weight-related condition, and Novo Nordisk said the 25-milligram tablet would launch in the United States in early January 2026. (ajmc.com; prnewswire.com) The Food and Drug Administration label says Wegovy tablets are also indicated to reduce the risk of major cardiovascular events — cardiovascular death, heart attack, or stroke — in adults with established cardiovascular disease and either obesity or overweight. (accessdata.fda.gov) The approval rests on the phase 3 OASIS 4 trial, which enrolled 307 adults without diabetes and compared oral semaglutide with placebo for 64 weeks. Patients on the pill lost 13.6% of body weight on average in the main analysis, versus 2.2% with placebo. (ajmc.com; acc.org) In a second trial estimate that assumed patients stayed on treatment as assigned, average weight loss reached 16.6% with oral semaglutide, versus 2.7% with placebo, and 34.4% of treated patients lost at least 20% of body weight. (acc.org; biospace.com) The bigger question is who benefits most and who gets the worst side effects. A Nature study published April 8, 2026, analyzed 27,885 people on glucagon-like peptide-1 drugs and found that a protein-changing variant in GLP1R, the drug’s target gene, was tied to greater weight loss. (nature.com) The same study linked variation in GLP1R and GIPR to nausea or vomiting, with the GIPR signal limited to people taking tirzepatide, a dual glucagon-like peptide-1 and gastric inhibitory polypeptide drug. The authors said those findings could help sort patients by likely benefit and side-effect risk before treatment starts. (nature.com) Outside clinical trials, results have been smaller. Cleveland Clinic researchers reported on June 10, 2025, that 7,881 adults treated with injectable semaglutide or tirzepatide in routine care lost less weight than patients in randomized trials, with early discontinuation and lower maintenance doses explaining much of the gap. (newsroom.clevelandclinic.org) In that study, more than 20% of patients stopped within three months, 32% stopped between three and 12 months, and more than 80% stayed on lower maintenance doses. Those numbers help explain why a pill option may widen access without guaranteeing trial-level results. (newsroom.clevelandclinic.org) The new tablet does not end the tradeoffs that have defined this drug class. It gives obesity treatment a needle-free entry point, while the genetics data and real-world drop-off data show that response, tolerability, and staying on therapy still shape what patients actually get from it. (accessdata.fda.gov; nature.com; newsroom.clevelandclinic.org)